Mass Spectrometry Facility

Welcome to the Barts Cancer Institute Mass Spectrometry Facility at Queen Mary University of London. We are a specialist core facility providing end-to-end support for proteomics, phosphoproteomics, metabolomics, and lipidomics using advanced high-resolution mass spectrometry (HRMS) platforms and optimised sample preparation workflows.

We work in close collaboration with researchers at all stages of their projects, offering support in experimental design, sample preparation, data acquisition, and downstream data analysis using commercial software to ensure robust and reproducible results.

Leveraging recent advances in mass spectrometry technology, the facility enables a wide range of applications in molecular and cellular biology, including characterisation of protein complexes, label-free quantitative proteomics, metabolomics and isotopic tracing, global lipidomic profiling, and the analysis of post-translational modifications, such as phosphorylation and acetylation.

Getting Started

For all enquiries, please contact the Faility Manager, Vinni Rajeeve, either by email (v.rajeeve@qmul.ac.uk), or by submitting a request via iLabs.

Back to top ↑

Acknowledgements and Authorship

All presentations and publications arising from work supported by these services should acknowledge the BCI Mass Spectrometry Facility.

Please include the following acknowledgement:

We wish to acknowledge the assistance of the BCI Mass Spectrometry Service, supported by a Cancer Research UK City of London Centre Grant (C355/A25137 XX).

For studies involving metabolomics analysis, please also include:

We acknowledge the Metabolic Flux Analysis Facility of the Queen Mary Faculty of Medicine and Dentistry, established with support from the Barts and The London Charity (grant number MGU0401).

We would also be grateful if copies of posters and published papers generated using these facilities could be sent to Dr Vinni Rajeeve.

Authorship

Where a member of Core Facility staff has made a substantial intellectual or experimental contribution to a study, they should be considered for co-authorship on the resulting publication.

Back to top ↑

Prices

There is a charge to cover mass spectrometry and reagent costs associated with sample preparation and analysis.

• Barts Cancer Institute users: Please refer to BCI Central for details.
• Queen Mary University of London users: Please contact Dr Vinni Rajeeve
• External users: Please contact Dr Vinni Rajeeve 

Back to top ↑

Training

The facility does not provide training for the independent operation of instruments. Unless otherwise directed, all sample preparation, LC–MS analysis, and data processing are handled by our expert staff to ensure high-quality, reproducible results.

Back to top ↑

Publications

• A novel inhibitor of soluble epoxide hydrolase that adducts C521 is cardioprotective. Redox Biol (2026). 89:103974. PMID: 41406572
• SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. EMBO Mol Med (2025). 17(8):2115-2136. PMID: 40640547
• RAS-p110α signalling in macrophages is required for effective inflammatory response and resolution of inflammation. eLife (2025). 13:RP94590. PMID: 40272400
• Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma. iScience (2024). 28(1):111525. PMID: 39758821
• Phosphoproteomic profiling of early rheumatoid arthritis synovium reveals active signalling pathways and differentiates inflammatory pathotypes. Arthritis Res Ther (2024). 26:120. PMID: 38867295
• Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes. Signal Transduct Target Ther (2023). 8:80. PMID: 36843114

Back to top ↑